Skip to main content
Top
Published in: Journal of Clinical Immunology 3/2015

01-04-2015 | Original Research

Long-Term Follow-up of STAT5B Deficiency in Three Argentinian Patients: Clinical and Immunological Features

Authors: Liliana Bezrodnik, Daniela Di Giovanni, María Soledad Caldirola, María Esnaola Azcoiti, Troy Torgerson, María Isabel Gaillard

Published in: Journal of Clinical Immunology | Issue 3/2015

Login to get access

Abstract

The signal transducer and activator of transcription (STAT) family of proteins regulate gene transcription in response to a variety of cytokines. STAT5B, in particular, plays an important role in T cells, where it is a key mediator of interleukin-2 (IL-2) induced responses. STAT5B deficiency causes a rare autosomal recessive disorder reported in only a handful of individuals. There are currently ten published cases of STAT5B deficiency, four of which are Argentinians.

Aim

This is a report of more than 10 years follow up of the clinical and immunological features of three Argentinian STAT5B deficient patients.

Conclusion

More than a decade of follow-up demonstrates that STAT5B deficiency is associated with various clinical pathologies that cause significant morbidity. Early diagnosis is critical for the prevention and improvement of clinical outcomes for STAT5B deficient patients.
Literature
1.
go back to reference Verbsky JW, Chatila TA. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. Curr Opin Pediatr. 2013;25(6):708–14.CrossRefPubMedPubMedCentral Verbsky JW, Chatila TA. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. Curr Opin Pediatr. 2013;25(6):708–14.CrossRefPubMedPubMedCentral
2.
go back to reference Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene. 2000;19(21):2566–76.CrossRefPubMed Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene. 2000;19(21):2566–76.CrossRefPubMed
4.
go back to reference Antov A et al. Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol. 2003;171(7):3435–41.CrossRefPubMed Antov A et al. Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol. 2003;171(7):3435–41.CrossRefPubMed
5.
go back to reference Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol. 2007;120(4):744–50. quiz 751–2.CrossRefPubMed Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol. 2007;120(4):744–50. quiz 751–2.CrossRefPubMed
6.
go back to reference Bernasconi A et al. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics. 2006;118(5):e1584–92.CrossRefPubMed Bernasconi A et al. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics. 2006;118(5):e1584–92.CrossRefPubMed
7.
go back to reference Cavallo MC, Llugdar J, Lozano NA, Pacoricona DL, Lozano A. Inmunodeficiencia primaria con deficit de crecimiento: rol de STAT5b. CIMEL. 2006;11:96–100. Cavallo MC, Llugdar J, Lozano NA, Pacoricona DL, Lozano A. Inmunodeficiencia primaria con deficit de crecimiento: rol de STAT5b. CIMEL. 2006;11:96–100.
8.
go back to reference Hwa V et al. Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res. 2007;68(5):218–24.CrossRefPubMed Hwa V et al. Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res. 2007;68(5):218–24.CrossRefPubMed
9.
go back to reference Hwa V et al. Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab. 2005;90(7):4260–6.CrossRefPubMed Hwa V et al. Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab. 2005;90(7):4260–6.CrossRefPubMed
10.
go back to reference Kofoed EM et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med. 2003;349(12):1139–47.CrossRefPubMed Kofoed EM et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med. 2003;349(12):1139–47.CrossRefPubMed
11.
go back to reference Pugliese-Pires PN et al. A novel STAT5B mutation causing GH insensitivity syndrome associated with hyperprolactinemia and immune dysfunction in two male siblings. Eur J Endocrinol. 2010;163(2):349–55.CrossRefPubMed Pugliese-Pires PN et al. A novel STAT5B mutation causing GH insensitivity syndrome associated with hyperprolactinemia and immune dysfunction in two male siblings. Eur J Endocrinol. 2010;163(2):349–55.CrossRefPubMed
12.
go back to reference Scaglia PA et al. A novel missense mutation in the SH2 domain of the STAT5B gene results in a transcriptionally inactive STAT5b associated with severe IGF-I deficiency, immune dysfunction, and lack of pulmonary disease. J Clin Endocrinol Metab. 2012;97(5):E830–9.CrossRefPubMed Scaglia PA et al. A novel missense mutation in the SH2 domain of the STAT5B gene results in a transcriptionally inactive STAT5b associated with severe IGF-I deficiency, immune dysfunction, and lack of pulmonary disease. J Clin Endocrinol Metab. 2012;97(5):E830–9.CrossRefPubMed
13.
go back to reference Vidarsdottir S et al. Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation. J Clin Endocrinol Metab. 2006;91(9):3482–5.CrossRefPubMed Vidarsdottir S et al. Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation. J Clin Endocrinol Metab. 2006;91(9):3482–5.CrossRefPubMed
14.
go back to reference Kanai T, Jenks J, Nadeau KC. The STAT5b pathway defect and autoimmunity. Front Immunol. 2012;14(3):234. Kanai T, Jenks J, Nadeau KC. The STAT5b pathway defect and autoimmunity. Front Immunol. 2012;14(3):234.
15.
go back to reference Cohen AC et al. Cutting edge: decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol. 2006;177(5):2770–4.CrossRefPubMed Cohen AC et al. Cutting edge: decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol. 2006;177(5):2770–4.CrossRefPubMed
17.
go back to reference Udy GB et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A. 1997;94(14):7239–44.CrossRefPubMedPubMedCentral Udy GB et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A. 1997;94(14):7239–44.CrossRefPubMedPubMedCentral
18.
go back to reference Ayling RM et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet. 1997;16(1):13–4.CrossRefPubMed Ayling RM et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet. 1997;16(1):13–4.CrossRefPubMed
19.
go back to reference Duquesnoy P et al. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. EMBO J. 1994;13(6):1386–95.PubMedPubMedCentral Duquesnoy P et al. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. EMBO J. 1994;13(6):1386–95.PubMedPubMedCentral
21.
go back to reference Burchill MA et al. Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J Immunol. 2003;171(11):5853–64.CrossRefPubMed Burchill MA et al. Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J Immunol. 2003;171(11):5853–64.CrossRefPubMed
23.
go back to reference Murawski MR et al. Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann N Y Acad Sci. 2006;1079:198–204.CrossRefPubMed Murawski MR et al. Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann N Y Acad Sci. 2006;1079:198–204.CrossRefPubMed
25.
go back to reference Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an immune dysregulation, polyendocvronophaty, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol. 2007;119:482.CrossRefPubMed Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an immune dysregulation, polyendocvronophaty, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol. 2007;119:482.CrossRefPubMed
26.
go back to reference Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, et al. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immun. 2013;146:248–61.CrossRef Goudy K, Aydin D, Barzaghi F, Gambineri E, Vignoli M, Ciullini Mannurita S, et al. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immun. 2013;146:248–61.CrossRef
27.
go back to reference Sharfe N, Dadi HK, Shahar M, Roifman CM. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci. 1997;94(7):3168–71.CrossRefPubMedPubMedCentral Sharfe N, Dadi HK, Shahar M, Roifman CM. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci. 1997;94(7):3168–71.CrossRefPubMedPubMedCentral
28.
29.
go back to reference Behbod F et al. Specific inhibition of Stat5a/b promotes apoptosis of IL-2-responsive primary and tumor-derived lymphoid cells. J Immunol. 2003;171(8):3919–27.CrossRefPubMed Behbod F et al. Specific inhibition of Stat5a/b promotes apoptosis of IL-2-responsive primary and tumor-derived lymphoid cells. J Immunol. 2003;171(8):3919–27.CrossRefPubMed
31.
go back to reference Goetz CA et al. STAT5 activation underlies IL7 receptor-dependent B cell development. J Immunol. 2004;172(8):4770–8.CrossRefPubMed Goetz CA et al. STAT5 activation underlies IL7 receptor-dependent B cell development. J Immunol. 2004;172(8):4770–8.CrossRefPubMed
32.
go back to reference Dorner T et al. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods. 2011;363(2):187–97.CrossRefPubMed Dorner T et al. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods. 2011;363(2):187–97.CrossRefPubMed
33.
go back to reference Snow JW et al. Bone marrow transplant completely rescues hematolymphoid defects in STAT5A/5B-deficient mice. Exp Hematol. 2003;31(12):1247–52.CrossRefPubMed Snow JW et al. Bone marrow transplant completely rescues hematolymphoid defects in STAT5A/5B-deficient mice. Exp Hematol. 2003;31(12):1247–52.CrossRefPubMed
Metadata
Title
Long-Term Follow-up of STAT5B Deficiency in Three Argentinian Patients: Clinical and Immunological Features
Authors
Liliana Bezrodnik
Daniela Di Giovanni
María Soledad Caldirola
María Esnaola Azcoiti
Troy Torgerson
María Isabel Gaillard
Publication date
01-04-2015
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 3/2015
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-015-0145-5

Other articles of this Issue 3/2015

Journal of Clinical Immunology 3/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.